PLAY PODCASTS
HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy
Episode 146

HABP/VABP and Gram-Negative Resistance: Pathways to Early Effective Therapy

Listen to expert insights on key concepts in HABP/VABP and gram-negative resistance management, including epidemiology, risk factors, burden of disease, diagnostics, and optimizing treatment regimens to minimize the time to effective therapy.

Decera Clinical Education Infectious Disease Podcast · Keith S. Kaye MD MPH, Lilian Abbo MD FIDSA, Jason M. Pogue PharmD

March 15, 20221h 41m

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Keith S. Kaye, MD, MPH; Lilian Abbo, MD, FIDSA; and Jason M. Pogue, PharmD, discuss HABP/VABP and gram-negative resistance including:

  • Epidemiology and burden of nosocomial bacterial pneumonia
  • Patient-specific risk factors for MDR pathogens
  • Improving outcomes with the use of antibiograms
  • Recommended empiric therapy for clinically suspected VABP
  • Antimicrobial resistance in HABP/VABP
  • Algorithms for gram-negative organism antibiotic-susceptibility testing
  • Using rapid diagnostic tests for HABP/VABP
  • New antimicrobial agents for MDR gram-negative infections with discussion of the 2021 IDSA guidance, and the following studies:
    • ASPECT-NP: ceftolozane/tazobactam vs meropenem
    • REPROVE: ceftazidime/avibactam vs meropenem
    • RESTORE-IMI-1 imipenem/cilastatin/relebactam vs colistin + imipenem
    • RESTORE-IMI-2: imipenem/cilastatin/relebactam vs piperacillin/tazobactam
    • APEKS-NP: cefiderocol vs meropenem
    • CREDIBLE-CR: cefiderocol vs best available therapy

Program Director:

Keith S. Kaye, MD, MPH
Chief
Division of Allergy, Immunology and Infectious Diseases
Professor of Medicine
Rutgers Robert Wood Johnson 
Medical School
New Brunswick, New Jersey

Faculty:

Lilian Abbo, MD, FIDSA
Associate Chief Medical Officer in Infectious Diseases
Jackson Health System
Professor of Infectious Diseases
Department of Medicine & Miami Transplant Institute
University of Miami Miller School of Medicine
Miami, Florida

Jason M. Pogue, PharmD
Clinical Professor
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Infectious Diseases Clinical Pharmacist
Michigan Medicine
Ann Arbor, Michigan

Content based on a CME program supported by an educational grant from Merck Sharp & Dohme Corp.

Follow along with a downloadable slideset at:
https://bit.ly/3CEop6h

Link to full program
 https://bit.ly/3i781lf


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

rdtalgorithmacinetobacteratsantibiogramunyverohospital-acquired bacterial pneumoniahabpapeks-npesblceftolozane/tazobactamidsa guidancecreceftazidime/avibactampdrcrabantimicrobial resistancetime to effective therapybiofirecredible-crcefepimeempiricimipenem/cilastatin/relebactamp aeruginosaenterobacteriaceaerapid diagnostic testrestore-imi-1stewardshiphapempiric therapydifficult to treathabp/vabpmeropenem/ vaborbactamextensively drug resistantventilator-associated bacterial pneumoniaventilator-associated pneumoniaantibiotic-susceptibility testingtobramycinidsaicureprovepiperacillin/tazobactammulti-drug resistanthospital-acquired pneumoniagram-negativecarbapenem-resistant acinetobactermdrinfection controlcefiderocol2016 idsa/atspan-drug resistanttteta baumanniinosocomial pneumoniahap/vaprestore-imi-2vancomycinaspect-nppseudomonasmeropenemxdrdtrklebsiellamolecular epidemiologyvabpvap